Literature DB >> 28290095

A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat.

Kimberly Becker1, Maha Saad2.   

Abstract

This article informs the reader of the current information available on a novel therapeutic agent and new class of drug for the treatment of anemia. The data show promising results for alternative erythropoietin-stimulating agents and offers a time line of when Phase III data will be available. The information on this new drug and new drug class will change how nephrologists approach treating anemia within their patients.

Entities:  

Keywords:  Anemia; Chronic kidney disease; Dialysis; Erythropoietin-stimulating agent; HIF-Inhibitor; Hematology; Hemoglobin; Nephrology; Non-dialysis; Roxadustat

Mesh：

Substances：

Year:  2017        PMID： 28290095     DOI： 10.1007/s12325-017-0508-9

Source DB:  PubMed          Journal:  Adv Ther        ISSN： 0741-238X            Impact factor:   3.845


  18 in total

Review 1.  Effectiveness of hypoxia-induced factor prolyl hydroxylase inhibitor for managing anemia in chronic kidney disease: a systematic review and meta-analysis.

Authors:  Min Li; Jiarong Lan; Feixia Dong; Peixin Duan
Journal:  Eur J Clin Pharmacol       Date:  2020-11-07       Impact factor: 2.953

Review 2.  The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.

Authors:  William G Kaelin
Journal:  Trans Am Clin Climatol Assoc       Date:  2017

3.  Hypoxia and the Prolyl Hydroxylase Inhibitor FG-4592 Protect Corneal Endothelial Cells From Mechanical and Perioperative Surgical Stress.

Authors:  Yogesh Bhadange; Jeferson Lautert; Shimin Li; Edward Lawando; Edward T Kim; Mark C Soper; Francis W Price; Marianne O Price; Joseph A Bonanno
Journal:  Cornea       Date:  2018-04       Impact factor: 2.651

4.  A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.

Authors:  Tadao Akizawa; Yusuke Yamaguchi; Tetsuro Otsuka; Michael Reusch
Journal:  Nephron       Date:  2020-06-24       Impact factor: 2.847

Review 5.  An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat.

Authors:  Kimberly A Becker; John J Jones
Journal:  Adv Ther       Date:  2017-12-28       Impact factor: 3.845

Review 6.  HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.

Authors:  Dalvir Kular; Iain C Macdougall
Journal:  Pediatr Nephrol       Date:  2018-03-22       Impact factor: 3.714

Review 7.  Roxadustat: First Global Approval.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2019-04       Impact factor: 9.546

8.  Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.

Authors:  Steven Fishbane; Mohamed A El-Shahawy; Roberto Pecoits-Filho; Bui Pham Van; Mark T Houser; Lars Frison; Dustin J Little; Nicolas J Guzman; Pablo E Pergola
Journal:  J Am Soc Nephrol       Date:  2021-02-10       Impact factor: 10.121

9.  Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects.

Authors:  Tomohisa Shibata; Yuki Nomura; Akitsugu Takada; Mai Ueno; Masataka Katashima; Rie Yazawa; Kenichi Furihata
Journal:  Clin Pharmacol Drug Dev       Date:  2018-07-02

10.  Population pharmacokinetics of roxadustat in Japanese dialysis-dependent chronic kidney disease patients with anaemia.

Authors:  Akitsugu Takada; Tomohisa Shibata; Takanori Shiga; Dorien Groenendaal-van de Meent; Kanji Komatsu
Journal:  Br J Clin Pharmacol       Date:  2021-09-02       Impact factor: 3.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.